以结构为指导的药物设计,准ABK:结构和监管如何帮助设计新药
Diego M Martins1, Philipe O Fernandes2, Lucas A Vieira1
1Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, 31270-901, Pampulha, MG, Brazil.
阿贝尔森酶 (Abl) 抑制剂对于慢性髓性白血病 (CML) 治疗至关重要,面临药物耐药性等挑战. 包括双价抑制剂和PROTACs在内的新策略正在开发中,以提高疗效和减少酶驱动疾病的副作用.
科学领域:
- 生物化学 生化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿贝尔森酶 (Abl) 是一个关键的氨酸酶,涉及慢性髓性白血病 (CML) 的病原体.
- 融合氨酸激酶Bcr-Abl瘤蛋白对CML的发展和治疗至关重要.
- 向疗法,特别是氨酸激酶抑制剂 (TKI),已经改变了CML患者的治疗结果.
研究的目的:
- 审查阿贝尔森酶抑制剂开发的进展.
- 突出克服耐药性和最小化副作用的策略.
- 探索ABl激酶研究对其他激酶驱动疾病的更广泛影响.
主要方法:
- 关于Abl激酶抑制剂的科学文献的综述.
- 强调基于结构和监管信息的合理药物设计.
- 讨论新兴的治疗策略,如双价抑制剂和PROTACs.
主要成果:
- 在开发Abl激酶抑制剂方面取得了显著进展,包括像伊马替尼布这样的TKIs.
- 识别挑战,如获得的耐药性和非目标毒性.
- 新策略的出现,以增强抑制剂的特异性和克服抵抗机制.
结论:
- 对于改善CML治疗来说,对ABL激酶抑制的持续研究至关重要.
- 先进的抑制剂设计对下一代针对酶驱动癌症的疗法具有前途.
- 了解Abl酶的结构和功能为开发对其他酶的抑制剂提供了洞察力.
更多相关视频
13:22Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Inhibition of Cdk Activity
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
